Tot Biopharma Approved to Launch Avastin Biosimilar in China

Suzhou Tot Biopharm announced that its Avastin biosimilar, Pusintin® (bevacizumab injection), has been approved to launch in China . It was proved to be clinically equivalent to Avastin a head-to-head comparisons in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer. Pusintin® is Tot's first antibody drug approved for marketing. Avastin is approved for six indications in China , and Pusintin will be approved for all six by extrapolation. More details.... Stock Symbol: (HK: 1875) Share this with colleagues: // //